Alison Stopeck, MD

Alison Stopeck, MD, is the Chief of the Division of Hematology/Oncology and a Professor of Medicine at Stony Brook University College of Medicine.  She is also the Associate Director for Clinical and Translational Research for the Stony Brook Cancer Center.  After receiving her bachelor’s degree from Brown University in Providence, Rhode Island, Dr. Stopeck completed her medical degree at Columbia University College of Physicians and Surgeons in New York City.  She remained at Columbia for a residency in internal medicine and then completed a fellowship in hematology/oncology at Cornell University Medical College.  She is a native Long Islander and moved to the Stony Brook Cancer Center in September 2014 where she focuses on breast cancer treatment and clinical trials.

Dr. Stopeck has authored or co-authored over 200 book chapters, refereed journal articles, abstracts, and editorials.  She is an associate editor for the American Journal of Medicine heading the hematology/oncology section.

She has been named as one of the Best Doctors in America, and America’s Top Doctors for Cancer.  She is a member of several professional organizations, including the American Association for Cancer Research and the American Society of Clinical Oncology.  Her breast cancer research interests include novel therapies, understanding the tumor microenvironment, and developing predictors of antitumor therapies or chemopreventive agents.

• Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases.
  
  von Moos R | Body JJ | Egerdie B | Stopeck A | Brown J | Fallowfield L | Patrick DL | Cleeland C | Damyanov D | Palazzo FS | Marx G | Zhou Y | Braun A | Balakumaran A | Qian Y
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  2016 Mar
  
  
• Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer.
  
  Brown-Glaberman U | Marron M | Chalasani P | Livingston R | Iannone M | Specht J | Stopeck AT
  Disease markers
  2016
  
  
• Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics.
  
  Lipton A | Fizazi K | Stopeck AT | Henry DH | Smith MR | Shore N | Martin M | Vadhan-Raj S | Brown JE | Richardson GE | Saad F | Yardley DA | Zhou K | Balakumaran A | Braun A
  European journal of cancer (Oxford, England : 1990)
  2016 Jan
  
  
• Pathophysiology of tumour-induced microangiopathic haemolytic anaemia.
  
  Chalasani P | Segar JM | Marron M | Stopeck A
  BMJ case reports
  2016
  
  
• A maximum-likelihood method to estimate a single ADC value of lesions using diffusion MRI.
  
  Jha AK | Rodriguez JJ | Stopeck AT
  Magnetic resonance in medicine
  2016 Jan 7
  
  
• Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
  
  Stopeck AT | Fizazi K | Body JJ | Brown JE | Carducci M | Diel I | Fujiwara Y | Martin M | Paterson A | Tonkin K | Shore N | Sieber P | Kueppers F | Karsh L | Yardley D | Wang H | Maniar T | Arellano J | Braun A
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  2016 Jan
  
  
• Intravenous thiotepa for treatment of breast cancer-related leptomeningeal carcinomatosis: case series.
  
  Chahal J | Stopeck A | Clarke K | Livingston RB | Chalasani P
  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  2015 Sep
  
  
• Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
  
  Body JJ | Bone HG | de Boer RH | Stopeck A | Van Poznak C | Damiao R | Fizazi K | Henry DH | Ibrahim T | Lipton A | Saad F | Shore N | Takano T | Shaywitz AJ | Wang H | Bracco OL | Braun A | Kostenuik PJ
  European journal of cancer (Oxford, England : 1990)
  2015 Sep
  
  
• A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer.
  
  Chalasani P | Marron M | Roe D | Clarke K | Iannone M | Livingston RB | Shan JS | Stopeck AT
  Cancer medicine
  2015 Jul
  
  
• The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.
  
  Diel IJ | Body JJ | Stopeck AT | Vadhan-Raj S | Spencer A | Steger G | von Moos R | Goldwasser F | Feng A | Braun A
  European journal of cancer (Oxford, England : 1990)
  2015 Jul
  
  
• EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.
  
  Yardley DA | Weaver R | Melisko ME | Saleh MN | Arena FP | Forero A | Cigler T | Stopeck A | Citrin D | Oliff I | Bechhold R | Loutfi R | Garcia AA | Cruickshank S | Crowley E | Green J | Hawthorne T | Yellin MJ | Davis TA | Vahdat LT
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  2015 May 10
  
  
• Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models.
  
  Chen LQ | Howison CM | Spier C | Stopeck AT | Malm SW | Pagel MD | Baker AF
  Leukemia & lymphoma
  2015 May
  
  
• Automated breast segmentation of fat and water MR images using dynamic programming.
  
  Rosado-Toro JA | Barr T | Galons JP | Marron MT | Stopeck A | Thomson C | Thompson P | Carroll D | Wolf E | Altbach MI | Rodriguez JJ
  Academic radiology
  2015 Feb
  
  
• Diffusion MRI with Semi-Automated Segmentation Can Serve as a Restricted Predictive Biomarker of the Therapeutic Response of Liver Metastasis.
  
  Stephen RM | Jha AK | Roe DJ | Trouard TP | Galons JP | Kupinski MA | Frey G | Cui H | Squire S | Pagel MD | Rodriguez JJ | Gillies RJ | Stopeck AT
  Magnetic resonance imaging
  2015 Dec
  
  
• Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
  
  Stopeck AT | Fizazi K | Body JJ | Brown JE | Carducci M | Diel I | Fujiwara Y | Martin M | Paterson A | Tonkin K | Shore N | Sieber P | Kueppers F | Karsh L | Yardley D | Wang H | Maniar T | Arellano J | Braun A
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  2015 Oct 19
  
  
• Isolation of viable cancer cells in antibody-functionalized microfluidic devices.
  
  Zheng X | Jiang L | Schroeder J | Stopeck A | Zohar Y
  Biomicrofluidics
  2014 Mar
  
  
• A pilot study of estradiol followed by exemestane for reversing endocrine resistance in postmenopausal women with hormone receptor-positive metastatic breast cancer.
  
  Chalasani P | Stopeck A | Clarke K | Livingston R
  The oncologist
  2014 Nov
  
  
• Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases.
  
  Matza LS | Cong Z | Chung K | Stopeck A | Tonkin K | Brown J | Braun A | Van Brunt K | McDaniel K
  Patient preference and adherence
  2013
  
  
• Impact of denosumab on bone mass in cancer patients.
  
  Brown-Glaberman U | Stopeck AT
  Clinical pharmacology : advances and applications
  2013
  
  
• Reply to Araki et al.
  
  Lipton A | Fizazi K | Stopeck AT | Henry DH | Braun AH
  European journal of cancer (Oxford, England : 1990)
  2013 Jun
  
  
• Authors' response to letter to the editor.
  
  Stopeck A | Henry D | Dansey R | Qian Y | Cong Z | Arellano J
  Journal of medical economics
  2013
  
  
• Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.
  
  Cleeland CS | Body JJ | Stopeck A | von Moos R | Fallowfield L | Mathias SD | Patrick DL | Clemons M | Tonkin K | Masuda N | Lipton A | de Boer R | Salvagni S | Oliveira CT | Qian Y | Jiang Q | Dansey R | Braun A | Chung K
  Cancer
  2013 Feb 15
  
  
• Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid.
  
  von Moos R | Body JJ | Egerdie B | Stopeck A | Brown JE | Damyanov D | Fallowfield LJ | Marx G | Cleeland CS | Patrick DL | Palazzo FG | Qian Y | Braun A | Chung K
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  2013 Dec
  
  
• Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.
  
  Martin M | Bell R | Bourgeois H | Brufsky A | Diel I | Eniu A | Fallowfield L | Fujiwara Y | Jassem J | Paterson AH | Ritchie D | Steger GG | Stopeck A | Vogel C | Fan M | Jiang Q | Chung K | Dansey R | Braun A
  Clinical cancer research : an official journal of the American Association for Cancer Research
  2012 Sep 1
  
  
• A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.
  
  Stopeck AT | Unger JM | Rimsza LM | LeBlanc M | Farnsworth B | Iannone M | Glenn MJ | Fisher RI | Miller TP
  Blood
  2012 Aug 9
  
  
• Task-based evaluation of segmentation algorithms for diffusion-weighted MRI without using a gold standard.
  
  Jha AK | Kupinski MA | Rodriguez JJ | Stephen RM | Stopeck AT
  Physics in medicine and biology
  2012 Jul 7
  
  
• A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer.
  
  Rugo HS | Chien AJ | Franco SX | Stopeck AT | Glencer A | Lahiri S | Arbushites MC | Scott J | Park JW | Hudis C | Nulsen B | Dickler MN
  Breast cancer research and treatment
  2012 Jul
  
  
• Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
  
  Stopeck A | Rader M | Henry D | Danese M | Halperin M | Cong Z | Qian Y | Dansey R | Chung K
  Journal of medical economics
  2012
  
  
• Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.
  
  Saad F | Brown JE | Van Poznak C | Ibrahim T | Stemmer SM | Stopeck AT | Diel IJ | Takahashi S | Shore N | Henry DH | Barrios CH | Facon T | Senecal F | Fizazi K | Zhou L | Daniels A | Carriere P | Dansey R
  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
  2012 May
  
  
• Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors.
  
  Brown-Glaberman U | Stopeck AT
  Biologics : targets & therapy
  2012
  
  
• Prevalence of depression in adults with haemophilia.
  
  Iannone M | Pennick L | Tom A | Cui H | Gilbert M | Weihs K | Stopeck AT
  Haemophilia : the official journal of the World Federation of Hemophilia
  2012 Nov
  
  
• Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
  
  Lipton A | Fizazi K | Stopeck AT | Henry DH | Brown JE | Yardley DA | Richardson GE | Siena S | Maroto P | Clemens M | Bilynskyy B | Charu V | Beuzeboc P | Rader M | Viniegra M | Saad F | Ke C | Braun A | Jun S
  European journal of cancer (Oxford, England : 1990)
  2012 Nov
  
  
• The role of targeted therapy and biomarkers in breast cancer treatment.
  
  Stopeck AT | Brown-Glaberman U | Wong HY | Park BH | Barnato SE | Gradishar WJ | Hudis CA | Rugo HS
  Clinical & experimental metastasis
  2012 Oct
  
  
• How do we define efficacy in comparing osteoclast-targeted agents in metastatic breast cancer?
  
  Gralow JR | Lipton A | Stopeck AT
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  2011 Sep 10
  
  
• HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
  
  Modi S | Stopeck A | Linden H | Solit D | Chandarlapaty S | Rosen N | D'Andrea G | Dickler M | Moynahan ME | Sugarman S | Ma W | Patil S | Norton L | Hannah AL | Hudis C
  Clinical cancer research : an official journal of the American Association for Cancer Research
  2011 Aug 1
  
  
• Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.
  
  Rugo HS | Stopeck AT | Joy AA | Chan S | Verma S | Lluch A | Liau KF | Kim S | Bycott P | Rosbrook B | Bair AH | Soulieres D
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  2011 Jun 20
  
  
• Systemic treatment of early breast cancer--a biological perspective.
  
  Greenberg S | Stopeck A | Rugo HS
  Journal of surgical oncology
  2011 May 1
  
  
• Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors.
  
  Gerber DE | Stopeck AT | Wong L | Rosen LS | Thorpe PE | Shan JS | Ibrahim NK
  Clinical cancer research : an official journal of the American Association for Cancer Research
  2011 Nov 1
  
  
• Caring for the breast cancer survivor: a guide for primary care physicians.
  
  Chalasani P | Downey L | Stopeck AT
  The American journal of medicine
  2010 Jun
  
  
• A Clustering Algorithm for Liver Lesion Segmentation of Diffusion-Weighted MR Images.
  
  Jha AK | Rodriguez JJ | Stephen RM | Stopeck AT
  Proceedings / IEEE Southwest Symposium on Image Analysis and Interpretation. IEEE Southwest Symposium on Image Analysis and Interpretation
  2010 May 23
  
  
• Denosumab findings in metastatic breast cancer.
  
  Stopeck A
  Clinical advances in hematology & oncology : H&O
  2010 Mar
  
  
• Evaluating segmentation algorithms for diffusion-weighted MR images: a task-based approach.
  
  Jha AK | Kupinski MA | Rodriguez JJ | Stephen RM | Stopeck AT
  Proceedings of SPIE--the International Society for Optical Engineering
  2010 Feb 27
  
  
• A case of metaplastic carcinoma of the breast responsive to chemotherapy with Ifosfamide and Etoposide: improved antitumor response by targeting sarcomatous features.
  
  Brown-Glaberman U | Graham A | Stopeck A
  The breast journal
  2010 Nov-Dec
  
  
• Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
  
  Stopeck AT | Lipton A | Body JJ | Steger GG | Tonkin K | de Boer RH | Lichinitser M | Fujiwara Y | Yardley DA | Viniegra M | Fan M | Jiang Q | Dansey R | Jun S | Braun A
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  2010 Dec 10
  
  
• Changes in body weight and metabolic indexes in overweight breast cancer survivors enrolled in a randomized trial of low-fat vs. reduced carbohydrate diets.
  
  Thomson CA | Stopeck AT | Bea JW | Cussler E | Nardi E | Frey G | Thompson PA
  Nutrition and cancer
  2010
  
  
• Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I trial.
  
  Thompson PA | Hsu CH | Green S | Stopeck AT | Johnson K | Alberts DS | Chow HH
  Cancer prevention research (Philadelphia, Pa.)
  2010 Jan
  
  
• A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.
  
  Stopeck AT | Unger JM | Rimsza LM | Bellamy WT | Iannone M | Persky DO | Leblanc M | Fisher RI | Miller TP
  Leukemia & lymphoma
  2009 May
  
  
• Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia.
  
  Gerstner G | Damiano ML | Tom A | Worman C | Schultz W | Recht M | Stopeck AT
  Haemophilia : the official journal of the World Federation of Hemophilia
  2009 Mar
  
  
• Metabolic syndrome and elevated C-reactive protein in breast cancer survivors on adjuvant hormone therapy.
  
  Thomson CA | Thompson PA | Wright-Bea J | Nardi E | Frey GR | Stopeck A
  Journal of women's health (2002)
  2009 Dec
  
  
• A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer.
  
  Gordon MS | Mendelson D | Carr R | Knight RA | Humerickhouse RA | Iannone M | Stopeck AT
  Cancer
  2008 Dec 15
  
  
• Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.
  
  DeAngelo DJ | Yu D | Johnson JL | Coutre SE | Stone RM | Stopeck AT | Gockerman JP | Mitchell BS | Appelbaum FR | Larson RA
  Blood
  2007 Jun 15
  
  
• Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
  
  Modi S | Stopeck AT | Gordon MS | Mendelson D | Solit DB | Bagatell R | Ma W | Wheler J | Rosen N | Norton L | Cropp GF | Johnson RG | Hannah AL | Hudis CA
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  2007 Dec 1
  
  
• Diagnosing and treating breast cancer in elderly women: a call for improved understanding.
  
  Downey L | Livingston R | Stopeck A
  Journal of the American Geriatrics Society
  2007 Oct
  
  
• What happened to the coxibs on the way to the cardiologist?
  
  Alberts DS | Potter JD | Martinez ME | Hess LM | Stopeck A | Lance P
  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  2005 Mar
  
  
• Women's health: the struggle to restore hormonal balance.
  
  Stopeck AT
  The American journal of medicine
  2005 Nov
  
  
• Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
  
  O'Farrell AM | Yuen HA | Smolich B | Hannah AL | Louie SG | Hong W | Stopeck AT | Silverman LR | Lancet JE | Karp JE | Albitar M | Cherrington JM | Giles FJ
  Leukemia research
  2004 Jul
  
  
• Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy.
  
  Theilmann RJ | Borders R | Trouard TP | Xia G | Outwater E | Ranger-Moore J | Gillies RJ | Stopeck A
  Neoplasia (New York, N.Y.)
  2004 Nov-Dec
  
  
• Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
  
  Zangari M | Anaissie E | Stopeck A | Morimoto A | Tan N | Lancet J | Cooper M | Hannah A | Garcia-Manero G | Faderl S | Kantarjian H | Cherrington J | Albitar M | Giles FJ
  Clinical cancer research : an official journal of the American Association for Cancer Research
  2004 Jan 1
  
  
• SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
  
  Giles FJ | Stopeck AT | Silverman LR | Lancet JE | Cooper MA | Hannah AL | Cherrington JM | O'Farrell AM | Yuen HA | Louie SG | Hong W | Cortes JE | Verstovsek S | Albitar M | O'Brien SM | Kantarjian HM | Karp JE
  Blood
  2003 Aug 1
  
  
• Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
  
  Giles FJ | Cooper MA | Silverman L | Karp JE | Lancet JE | Zangari M | Shami PJ | Khan KD | Hannah AL | Cherrington JM | Thomas DA | Garcia-Manero G | Albitar M | Kantarjian HM | Stopeck AT
  Cancer
  2003 Apr 15
  
  
• Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
  
  Stopeck A | Sheldon M | Vahedian M | Cropp G | Gosalia R | Hannah A
  Clinical cancer research : an official journal of the American Association for Cancer Research
  2002 Sep
  
  
• Radial fast spin-echo method for T2-weighted imaging and T2 mapping of the liver.
  
  Altbach MI | Outwater EK | Trouard TP | Krupinski EA | Theilmann RJ | Stopeck AT | Kono M | Gmitro AF
  Journal of magnetic resonance imaging : JMRI
  2002 Aug
  
  
• Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast.
  
  Coronella JA | Spier C | Welch M | Trevor KT | Stopeck AT | Villar H | Hersh EM
  Journal of immunology (Baltimore, Md. : 1950)
  2002 Aug 15
  
  
• Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.
  
  Stopeck AT | Jones A | Hersh EM | Thompson JA | Finucane DM | Gutheil JC | Gonzalez R
  Clinical cancer research : an official journal of the American Association for Cancer Research
  2001 Aug
  
  
• Cationic lipid gene transfer of an IL-2 transgene leads to activation of natural killer cells in a SCID mouse human tumor xenograft.
  
  Clark PR | Stopeck AT | Parker SE | Hersh EM
  Cellular immunology
  2000 Sep 15
  
  
• Studies of direct intratumoral gene transfer using cationic lipid-complexed plasmid DNA.
  
  Clark PR | Stopeck AT | Ferrari M | Parker SE | Hersh EM
  Cancer gene therapy
  2000 Jun
  
  
• Construction of new amplifier expression vectors for high levels of IL-2 gene expression.
  
  Tsang TC | Brailey JL | Vasanwala FH | Wu RS | Liu F | Clark PR | Meade-Tollin L | Luznick L | Stopeck AT | Akporiaye ET | Harris DT
  International journal of molecular medicine
  2000 Mar
  
  
• Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma.
  
  Stopeck AT | Gessner A | Miller TP | Hersh EM | Johnson CS | Cui H | Frutiger Y | Grogan TM
  Clinical cancer research : an official journal of the American Association for Cancer Research
  2000 Oct
  
  
• Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience.
  
  Galanis E | Hersh EM | Stopeck AT | Gonzalez R | Burch P | Spier C | Akporiaye ET | Rinehart JJ | Edmonson J | Sobol RE | Forscher C | Sondak VK | Lewis BD | Unger EC | O'Driscoll M | Selk L | Rubin J
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  1999 Oct
  
  
• Polycations and cationic lipids enhance adenovirus transduction and transgene expression in tumor cells.
  
  Clark PR | Stopeck AT | Brailey JL | Wang Q | McArthur J | Finer MH | Hersh EM
  Cancer gene therapy
  1999 Sep-Oct
  
  
• Transfection of primary tumor cells and tumor cell lines with plasmid DNA/lipid complexes.
  
  Stopeck AT | Hersh EM | Brailey JL | Clark PR | Norman J | Parker SE
  Cancer gene therapy
  1998 Mar-Apr
  
  
• Human gene therapy for melanoma: CT-guided interstitial injection.
  
  Waddill W 3rd | Wright W Jr | Unger E | Stopeck A | Akporiaye E | Harris D | Grogan T | Schluter S | Hersh E | Stahl S
  AJR. American journal of roentgenology
  1997 Jul
  
  
• Transfer and expression of the interferon gamma gene in human endothelial cells inhibits vascular smooth muscle cell growth in vitro.
  
  Stopeck AT | Vahedian M | Williams SK
  Cell transplantation
  1997 Jan-Feb
  
  
• Advances in the biological therapy and gene therapy of malignant disease.
  
  Hersh EM | Stopeck AT
  Clinical cancer research : an official journal of the American Association for Cancer Research
  1997 Dec
  
  
• Recent advances in the treatment of malignant melanoma with gene therapy.
  
  Hersh EM | Stopeck AT
  Molecular medicine (Cambridge, Mass.)
  1997 Oct
  
  
• Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma.
  
  Stopeck AT | Hersh EM | Akporiaye ET | Harris DT | Grogan T | Unger E | Warneke J | Schluter SF | Stahl S
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  1997 Jan
  
  
• Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo.
  
  Parker SE | Khatibi S | Margalith M | Anderson D | Yankauckas M | Gromkowski SH | Latimer T | Lew D | Marquet M | Manthorpe M | Hobart P | Hersh E | Stopeck AT | Norman J
  Cancer gene therapy
  1996 May-Jun
  
  
• Interferon gamma (IFNgamma) gene transfer of an EMT6 tumor that is poorly responsive to IFNgamma stimulation: increase in tumor immunogenicity is accompanied by induction of a mouse class II transactivator and class II MHC.
  
  Panelli MC | Wang E | Shen S | Schluter SF | Bernstein RM | Hersh EM | Stopeck A | Gangavalli R | Barber J | Jolly D | Akporiaye ET
  Cancer immunology, immunotherapy : CII
  1996 Feb
  
  
• Phase I study of immunotherapy of malignant melanoma by direct gene transfer.
  
  Hersh EM | Akporiaye E | Harris D | Stopeck AT | Unger EC | Warneke JA | Kradjian SA
  Human gene therapy
  1994 Nov